The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania by Mori, Amani Thomas et al.
The Role of Evidence in the Decision-Making Process of
Selecting Essential Medicines in Developing Countries:
The Case of Tanzania
Amani Thomas Mori1,2*, Eliangiringa Amos Kaale2, Frida Ngalesoni1,3, Ole Frithjof Norheim1,
Bjarne Robberstad1
1Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway, 2 School of Pharmacy, Muhimbili University
of Health and Allied Sciences, Dar es Salaam, Tanzania, 3Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
Abstract
Background: Insufficient access to essential medicines is a major health challenge in developing countries. Despite the
importance of Standard Treatment Guidelines and National Essential Medicine Lists in facilitating access to medicines, little
is known about how they are updated. This study aims to describe the process of updating the Standard Treatment
Guidelines and National Essential Medicine List in Tanzania and further examines the criteria and the underlying evidence
used in decision-making.
Methods: This is a qualitative study in which data were collected by in-depth interviews and document reviews. Interviews
were conducted with 18 key informants who were involved in updating the Standard Treatment Guidelines and National
Essential Medicine List. We used a thematic content approach to analyse the data.
Findings: The Standard Treatment Guidelines and National Essential Medicine List was updated by committees of experts
who were recruited mostly from referral hospitals and the Ministry of Health and Social Welfare. Efficacy, safety, availability
and affordability were the most frequently utilised criteria in decision-making, although these were largely based on
experience rather than evidence. In addition, recommendations from international guidelines and medicine promotions also
influenced decision-making. Cost-effectiveness, despite being an important criterion for formulary decisions, was not
utilised.
Conclusions: Recent decisions about the selection of essential medicines in Tanzania were made by committees of experts
who largely used experience and discretionary judgement, leaving evidence with only a limited role in decision-making
process. There may be several reasons for the current limited use of evidence in decision-making, but one hypothesis that
remains to be explored is whether training experts in evidence-based decision-making would lead to a better and more
explicit use of evidence.
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Introduction
Insufficient access to essential medicines is a major health
challenge in developing countries; among poor populations more
than half have been estimated to lack regular access to medicines
[1]. Shortages of essential medicines are common in publicly-
financed facilities, which constitute a major part of the health
systems in most developing countries [2,3], and which are
especially important for poor families seeking affordable services
[4]. Commonly mentioned problems are insufficient public
spending on pharmaceuticals, the high cost of medicines and
challenges in the supply chains [3,4]. Efforts to improve access to
essential medicines have been revitalised by the Millennium
Development Goals [5] and a renewed global focus on Primary
Health Care [6].
The essential medicines programme entails stocking a limited
range of efficacious, safe and cost-effective medicines that are
sufficient to meet the priority health needs of the people [7]. For
many countries, essential medicines are those recommended in
their treatment guidelines [8]. Consistent and appropriate use of
adequately developed treatment guidelines and formularies
improve the availability and use of medicines [8,9,10], and their
effective implementation not only increases efficiency in resource
use but also improves access and the overall quality of care
[11,12,13].
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The Essential Medicines Programme in Tanzania:
Historical Perspective
Tanzania, one of the pioneers of the essential medicines
programme, produced its first list of essential medicines in the
early 1970s [14,15]. The programme was later adopted by the
WHO, and in 1977 the first WHO modal list of essential drugs
was produced [16]. In 1978, the provision of essential medicines
was declared to be one of the key elements of Primary Health Care
through the Alma Ata Declaration [17]. In 1990, Tanzania
produced a national health policy document for the first time,
adopting the Primary Health Care approach as its cornerstone
strategy [18]. A year later, the country launched its first Standard
Treatment Guidelines and National Essential Medicine List
(STG/NEML) [19], which has subsequently been revised three
times. The STG contains recommendations about appropriate
healthcare decisions for common disease conditions in Tanzania
and the NEML specifies the type of medicines and level of
healthcare facility for which they should be made available. The
NEML is also used to guide the procurement and supply of
medicines in the public sector [11].
Tanzanian Healthcare System
Tanzania is categorised as a low-income country with a per
capita expenditure on health of about 41 US$ per year [20]. The
healthcare system has a pyramid structure, with tertiary facilities at
the apex and primary facilities at the base; in between these lie the
regional and district facilities. The Government owns about three-
quarters of all healthcare facilities, while the rest are private, with
some belonging to faith-based organizations [21]. As in other sub-
Saharan African countries, the burden of disease is dominated by
infectious diseases [22] and about 60 per cent of medicines listed as
essential have been estimated to be available in district and
primary facilities [23]. Indicators show that the Tanzanian health
system is facing large challenges, including a relatively low life
expectancy and relatively high infant, child and maternal mortality
rates (Table 1).
Essential Medicine Selection in Developing Countries
Most developed countries have health technology assessment
(HTA) systems, such as the National Institute of Clinical
Excellence (NICE) in the UK and the Canadian Agency for
Drugs and Technology in Health (CADTH), which issue
formulary recommendations for reimbursement decisions. Cost-
effectiveness evaluation is a mandatory criterion employed to
inform decision-making [26,27]. By contrast, essential medicines
in developing countries, including Tanzania, are selected by expert
committees that supposedly use the WHO’s guidelines, which
recommend selection to be based on evidence of efficacy, safety,
cost and cost-effectiveness [28]. However, the extent to which the
evidence-based approach has been implemented in developing
countries is not well documented. Therefore this study aims to
describe the process of updating the Standard Treatment
Guidelines and National Essential Medicine List in Tanzania




The study was approved by the Ethical Review Committee of
the Tanzania National Institute of Medical Research. The study
was conducted during a period when there was a medical doctors’
strike in the country and therefore we anticipated challenges in
obtaining written consents. This concern was communicated to
the ethics committee and authorisation was granted to use verbal
consent. After self-introduction, the purpose of the study was
explained to each informant and confidentiality was assured. All
the informants were nevertheless, cautiously, asked for written
consent before commencing the interviews, but they opted to give
verbal consent. Each informant was assigned a code number
which was entered on a consent form and signed to document that
verbal consent had been given. Furthermore, the interviews were
recorded with permission from the informants and the digital voice
recorder and the transcripts were kept confidential.
The Study Design
This qualitative study utilises a descriptive case study design,
which is an empirical inquiry that investigates a phenomenon
within its real-life context [29]. This design is useful when studying
complex and context-dependent undertakings, such as the
selection of essential medicines [30]. The descriptive design was
chosen in order to provide information-rich explanations of the
decision-making processes [29,31]. The study adheres to the
consolidated criteria for reporting qualitative research (COREQ)
[32].
The Research Team
The research team consisted of two doctoral students, a senior
researcher and two professors. ATM’s background is in pharmacy,
health policy analysis and management. FN’s background is in
medicine (MD) and health economics. EAK is a senior researcher
(PhD) and has outstanding experience with the ATLAS.tiH data
analysis software. OFN and BR are professors with extensive
experience of national guidelines and drug reimbursement
advisory committees in Norway.
Sampling and Sample Size
We used purposive sampling methods to select 18 information-
rich informants from the list of experts who participated in the
revision of the STG/NEML and two who did not participate, but
who were perceived to possess important information for the
study. We obtained this list, which contained the names,
professions, specialisations, institutions and phone and email
contacts, from the Ministry of Health and Social Welfare
(MoHSW). Some informants were contacted through phone calls
while others were visited at their work places. All the selected
informants agreed to participate in the study. Several other
informants were also involved in the study through informal
interviews which were conducted in order to broaden our
understanding of the inquiry.
Table 1. Selected demographic and health indicators for
Tanzania.
Indicator Data Source
Population 44.9 million Census, 2012 [24]
Life expectancy at birth 52 TDHS*, 2010
Fertility rates 5.4 TDHS, 2010
Infant mortality rate 51/1,000 TDHS, 2010
Under five mortality rate 81/1,000 TDHS, 2010
Maternal mortality rate 454/100,000 TDHS, 2010 [25]
*TDHS: Tanzania Demographic Health Survey.
doi:10.1371/journal.pone.0084824.t001
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Descriptions of Study Participants
In selecting the informants, we chose those who had experience
of participating in the previous revision process, but we also
wanted to have good professional, institutional and speciality
representations. Therefore our informants were pharmacists and
clinicians with different specialisations from referral, municipal
and specialised hospitals. Others were programme and section
officers from the MoHSW (Figure 1). The final two informants
were from the Food and Drugs Regulation Authority (TFDA).
Eight of the 20 key informants were females working in hospitals,
the MoHSW and the TFDA. Some of the participants,
particularly the pharmacists, knew the interviewer in person.
Data Collection Methods
In-depth interviews and document reviews were the main
methods of data collection and were carried out between June and
December 2012, while the revision of the STG/NEML was still
ongoing.
In-depth interviews. In-depth interviews were conducted
face to face with key informants, in English, using a pre-tested,
semi-structured interview guide. All formal interviews were
conducted in the offices of our informants and nobody else was
present during the conversations. Interviews were digitally
recorded and each lasted for 30–45 minutes. The 18 formal
interviews, including one repeat interview, with the STG/NEML
review group and the two additional in-depth interviews with
informants from the TFDA were sufficient for data saturation. In
addition, some informal interviews were conducted without the
interview guide.
Document reviews. Several documents containing informa-
tion related to the implementation of the essential medicines
programme in Tanzania were reviewed to supplement the
interview data. This included the STG/NEML of 2007 and
2012, the national drug policy, minutes and proceedings of the
review meetings, published reports and research articles. We
reviewed the malaria and HIV/AIDS treatment guidelines in
order to determine whether they are consistent with international
guidelines. The research team was already in possession of some of
these documents, which were used for a systematic review study
about the use of pharmacoeconomics as a criterion of medicine
selection in Tanzania [33].
Interview Guide
The interview guide contained questions and probes as
described below. The flow varied from one participant to another
depending on how the discussions unfolded. It was piloted with
four participants and, because no major changes were introduced
in the guide, we decided to include these interviews in the analysis.
The process of medicine selection. Informants were asked
to describe how the review process was conducted and probed
about how they became involved, how and by whom they were
contacted and their personal views about the process. Those from
the MoHSW who initiated and co-ordinated the process were in
addition probed about how they selected the participants, the
rationale for doing the review, composition of the committees etc.
Criteria for medicine selection. Informants were asked
about how they selected the medicines, the selection criteria, how
strictly the criteria were followed and to rank the criteria based on
their importance/strengths. For each criterion they mentioned,
they were probed to give the type and source of evidence and how
they evaluated such evidence.
Use of economic evaluation evidence. Informants were
asked whether they used economic analysis as a criterion if they
had not mentioned it before, and how and to what extent
economic evaluation was used (probed to give examples). They
were further probed about challenges that hinder the use of
economic evaluation and enabling factors for its use. Lastly they
were asked if they had received any training in health economics.
Data Management and Analysis
Verbatim data were transcribed into text using a standardised
transcription protocol [34]. Transcripts were loaded into AT-
LAS.ti 7 Qualitative Data Analysis Software and analysed using a
thematic content approach [35]. Each transcript was read
carefully to identify relevant segments of text, which were then
coded. Similar or related codes were organised into categories.
Quotations attached to the codes were read with constant
comparisons and the main descriptions were summarised in
memos. Data from the interviews and document reviews were
triangulated in memos. Finally, categories were organised under
their respective pre-defined themes.
Figure 1. Summary of the key milestones during the revision process.
doi:10.1371/journal.pone.0084824.g001
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Description of the Coding Tree
The coding tree consisted of three branches (themes); process,
criteria and evidence. Under process there were two categories;
the STG/NEML review and the approval process. Under criteria
we did not have categories but only the codes for each criterion.
Evidence was categorised as being drawn from experience and
scientific study or from official documents. Code names reflected
the content of each text segment.
Data Validity
Five measures were taken to ensure that the data obtained were
valid and trustworthy. Firstly, informants were contacted infor-
mally to create a platform for self-introduction, to explain the
purpose of the research and assure confidentiality. Secondly,
informants were purposively selected to maximise representation
of a wide range of perspectives on the subject. Thirdly, interviews
were recorded and then transcribed shortly after each interview
session to preserve the originality of the data. Fourthly, transcripts
were shared with the informants for cross-checking and validation,
after which ten of the 18 informants provided feedback, most of
them without any changes and a few with minor editing. Fifthly,
triangulation of data was performed to enrich and supplement the
information collected by interviews and document reviews.
Results
This section provides results about the STG/NEML revision
process, the criteria applied and the extent to which evidence was
utilised during decision-making. To illustrate the findings,
supporting verbatim quotes from the informants are provided.
Informants are only identified by their institutions in order to
avoid any breach of confidentiality.
Description of the Revision Process
The process of updating the STG/NEML was initiated in early
2012 by the Ministry of Health and Social Welfare (MoHSW).
The process was co-ordinated by the Pharmaceutical Service
Section (PSS) on behalf of the National Medicines and Thera-
peutic Committee (NMTC). The sequence of events is shown in
Figure 2. An official from the MoHSW gave the following
rationale for the revision.
The review was caused by two important things: first the number of
diseases had increased and the required medicines to manage such
diseases were not in the STG/NEML. Also it has been a long time
since the existing STG/NEML was revised and there have been some
new developments and changes in how certain diseases are managed in
clinical practice. Basically, the WHO recommends revision after every
2–3 years. (Participant from the MoHSW)
To begin the review process, the PSS convened an internal
meeting to establish a committee of experts, known as ‘a guideline
review secretariat’ to revise the STG first; this was important
because only those medicines recommended in the STG are listed
in the NEML. One official explained:
First we had an internal meeting where we decided the kind of people to
involve in the process; we wanted a mixture of people from primary to
tertiary-level facilities, including people from various programmes.
Therefore we consulted people from the malaria and HIV/AIDS
control programmes who had the experience of reviewing their treatment
guidelines and they gave us guidance about who we should involve in the
review process. (Participant from the MoHSW)
The STG/NEML document has two parts; the STG part
contains 25 chapters covering common diseases in Tanzania, their
clinical signs and symptoms, how they should be diagnosed and
the recommended treatments or supportive care. The NEML part
contains the list of all medicines that are recommended in the
STG. It uses generic names and the medicines are arranged
according to their pharmacological groups. The NEML also
specifies the dosage form, its strength and the level of healthcare
facilities where each medicine should be made available.
The guideline review secretariat. The guideline review
secretariat was composed of a multidisciplinary team of experts
(Figure 1) who were mostly selected and invited by the MoHSW.
Nearly two-thirds of the experts came from referral hospitals,
specialised hospitals and the MoHSW, and these were mainly
physicians and specialists. Half of them were female. Through
document review we found that only three had been involved in
the previous review of the STG/NEML. Two informants said they
had received training on evidence-informed decision-making. One
of these said:
When I was pursuing my masters at […] we were at times being taught
by people from foreign universities such as […] so they emphasised the
use of evidence, particularly from meta-analyses in decision-making.
(Participant from Hospital)
The revision of the Standard Treatment Guidelines. At
its first meeting, the secretariat discussed the approach to update
the STG. A consensus was reached to split into groups according
to medical specialities to simplify and speed up the revision
process. Each group was tasked with revising a specific section of
the guidelines pertaining to its speciality. One informant said:
We started the review process by going through the old STG first;
looking at what was missing, what to add and even what should be
removed completely. We went through each disease condition one after
another but not as a single panel. We were divided into specialities,
people dealing with cancer looked at cancers, cardiology the same etc.
(Participant from Hospital)
The revision process varied between groups; some groups
organised discussion meetings and disseminated their recommen-
dations around their respective departments for comment, while in
other groups the task was a take-home assignment for group
members. The majority of informants said that the organisation,
participation and time allocated to the task were not satisfactory.
In my opinion the process is not perfect. First of all the time for review is
very constrained, in such a way that you cannot have effective and
detailed discussions on the management of patients and other important
issues. (Participant from Hospital)
The process was so disorganised, I remember I presented the work of
another person who was not there […]. I can say the whole
organisation was not good. (Participant from Hospital)
During the second meeting, group leaders presented the
proposed recommendations to the secretariat so that other
members could provide comments. Thereafter, these group works
were compiled into a first draft of the STG. The PSS then
extracted all the recommended medicines from this guideline to
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formulate the NEML. The draft of the STG/NEML was
disseminated to different experts before it was submitted to the
National Medicines and Therapeutic Committee (NMTC) for
approval. One informant said:
The draft of the STG/NEML was sent to the panel of reviewers for
comment. Most of our reviewers come from major hospitals; we believe
they have experience in research and publications. Then, after receiving
their comments, we addressed them before we sent the document to the
National Therapeutic Committee for approval. (Participant from the
MoHSW)
Criteria used for Medicine Selection and the Underlying
Evidence
The criteria employed and level of evidence varied between the
groups updating different sections of the STG; some groups
considered only one criterion while others used several. These
criteria, together with their supporting evidence and other factors
that influenced decision-making, are described below.
Efficacy and safety. A majority of informants said that they
used an evidence-based approach in updating the STG/NEML.
Efficacy and safety were the most cited criteria to have been used
by different informants from the guideline review groups. Two
informants said:
We were using an evidence-based approach that a recommended drug
must have shown that clinically it was more potent and produced more
benefits and there is research evidence for that. (Participant from
Hospital)
At the time of the review […] was a hot cake, people were trying to
assess whether it was safe for patients. In general the concern was how it
fares in the field as compared to […]; there were some discussions and
we reached a consensus as you saw in the guidelines. (Participant
from Hospital)
Regarding the use of evidence, all informants acknowledged
that evidence summaries for these criteria were not generated to
inform decision-making, but claimed that such evidence was
known to them through clinical experience. Two informants said:
Clinical experience was crucial, because you want to produce a practical
guideline. Therefore frankly speaking, a lot of evidence came from my
daily practice and this was not scientific evidence but simply my
experience. (Participant from Hospital)
Doctors were the ones who were recommending medicines for the
Standard Treatment Guidelines to manage diseases through their
clinical practice. Our belief was that as long as the medicine is being
used in the hospital then automatically there was clinical evidence for
that medicine to be selected. (Participant from MoHSW)
The two informants who mentioned being trained in evidence-
informed decision-making said that their recommendations were
supported by research evidence from clinical trials and meta-
analyses. However, during the interviews, as well as saying they
did not develop evidence summaries, they were also not able to
give sufficient explanation about how they searched and appraised
the evidence. Some informants, particularly the pharmacists,
recognised the lack of evidence in the decision-making process.
One member of the secretariat expressed the following concern:
We asked the physicians if the evidence they were giving to support their
recommendations was actually based on scientific research! Unfortu-
nately no one said it was scientific evidence. They all said the evidence
was observation from their clinical practice and feedback from their
patients. (Participant from Hospital)
In some situations the interviewer challenged the informants
with scientific evidence supporting the use of some medicines for a
condition other than the one they had recommended. Surprising-
ly, some informants disagreed with such evidence, which was
another indication of how difficult it was for scientific evidence to
Figure 2. Composition and institutional representation of the guideline review Secretariat.
doi:10.1371/journal.pone.0084824.g002
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find its way onto the decision-making table compared with that
from clinical experience. One such example is Tranexamic Acid
(TXA) injection, a drug which reduces the risk of death in bleeding
trauma patients [36]. In the STG it is recommended for
prevention of mucosal bleeding. One informant said:
I have never heard of any clinical trials done on tranexamic acid
injection. I do not agree or believe in that research, it is not correct.
Tranexamic acid is not a treatment, it is prevention and it is
contraindicated in massive injuries. How can it help when someone has
massive bleeding? (Participant from Hospital)
Availability. All informants said that it is very important that
the medicines they select are available on the Tanzanian market so
that patients can access them even when they are not available at
public healthcare facilities. They said that the existing policy
requires all medicines in the STG/NEML to be written with
generic names rather than brand names because generics are
readily available, relatively cheap and affordable.
We asked ourselves whether the medicines we were selecting were
actually available in the market. The main question was: if a certain
medicine in the list was prescribed will it be available in the Tanzanian
market? We thought it would not make sense to have medicines in the
STG/NEML which were not readily available in the country.
(Participant from Hospital)
Informants from the Tanzania Food and Drugs Authority
(TFDA) said that the availability of medicines depends on whether
they are registered in Tanzania or not. They said that in order for
any medicine to be allowed to enter the Tanzanian market it has
to go through a rigorous registration process in which its quality,
efficacy and safety are thoroughly checked. They said that the
TFDA registers all medicines that meet a minimum level of
prescribed standards and it is from this pool that essential
medicines are selected. One official explained:
Drug registration actually involves many processes. In summary, the
applicant, usually the manufacturer of the drug, must provide detailed
information about the active pharmaceutical ingredient, the finished
product and good manufacturing process which demonstrates the quality,
safety and efficacy of the drug product. (Participant from the
TFDA)
None of the informants mentioned having used the list of
registered medicines from the TFDA. Instead they said they knew
the available medicines through their practice. Through the
interviews we learned that healthcare workers in Tanzania
frequently receive drug information from representatives from
pharmaceutical companies. One informant said:
We communicate a lot with our colleagues working with pharmaceutical
companies, so they tell us if there are new drugs as first lines for certain
diseases with better clinical outcomes. (Participant from Hospital)
Affordability. A majority of informants said that affordability
was an important criterion in medicine selection because
economically Tanzania is very poor. Despite this concession,
some informants said that there were disagreements between the
doctors and pharmacists about the limit on the number of
medicines to be added to the STG/NEML and whether expensive
medicines should also be selected. Some doctors wanted the STG
to have a variety of medicines from different therapeutic classes for
each disease, some of which were considered expensive. Pharma-
cists, as the custodians of medicines, often opposed them because
they were concerned about budget implications. There was no
consensus about these disputes and the final ruling awaited the
approval meeting of the National Medicines and Therapeutic
Committee. One informant said:
There were disagreements between me and the doctors, I told them
essential medicine means to have a limited number of affordable
medicines but they said ‘‘No! We are the ones who are in the field
treating patients’’. Therefore there is a need for people to be educated
about the meaning of essential medicines. (Participant from
Hospital)
Informants said that they also took into account the total cost of
treatment rather than the unit prices of individual medicines,
especially for chronic diseases. One informant said:
In some cases we looked at costs for a full course of treatment rather than
unit prices. A month’s cost of a 50 Tanzanian shilling (Tshs) tablet
taken three times a day is 4,500 Tshs compared to 3,000 Tshs for a
once-a-day sustained-release tablet which costs 100 Tshs. You see, this
is cheaper and increases compliance with treatment. (Participant from
Hospital)
Regarding the evidence for medicine prices, the majority said
they knew the prices of most medicines through experience but
some said they used price lists from the Medical Stores
Department and drug representatives from private medicine
suppliers. One informant said:
So if two drugs were equally efficacious but one is cheaper then we
selected the cheaper one so long as it has acceptable quality. We used the
price list from the Medical Stores Department to compare the costs of the
drugs. (Participant from Hospital)
Cost-effectiveness. The understanding of cost-effectiveness
analysis was poor among the majority of informants. Some
confused it with cost comparisons and others were completely
unaware of the concept. Those who said they were aware of it said
that cost-effectiveness was not used as a criterion for medicine
selection. They went on to say that economic evaluation studies
are scarce in the country, and even if they were available they
could not use them because they lack expertise.
Two informants said the following:
Economic evaluation was not used at all. I think that means there
should have been some studies about economic evaluation of medicines in
Tanzania, which I am not sure if there is. Honestly, we have not taken
on board such a criterion in the medicine selection process. (Participant
from the MoHSW)
Well, that one I cannot say much about since it is not part of our
expertise. I don’t remember in our group talking anything about
economic evaluation of medicines, maybe in other groups but not the one
I was with. (Participant from Hospital)
Only one informant said he had received training about the use
of economic evidence. Amongst the others, besides saying this was
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not an area in which they had expertise, one went further to
comment that:
Perhaps in the future, use of economic evaluation should be emphasised
and the team involved in the review should be given lectures on
pharmacoeconomics so that they can have knowledge about other criteria
for inclusion of medicines in the Standard Treatment Guidelines besides
clinical reasons. (Participant from Hospital)
Other Factors that Influenced Decision-making
International recommendations. Informants said that
Tanzania has vertical programmes for HIV/AIDS, malaria,
tuberculosis and leprosy. These programmes have their own
guidelines, which are updated based on global recommendations.
These recommendations were adopted in the STG. In addition,
some informants said that they copied their recommendations
from textbooks and guidelines from countries such as the USA,
South Africa, Ghana and Lesotho. Regarding the use of
international guidelines, one informant said:
With malaria we follow the global recommendations, for example in
2010, the WHO malaria treatment guidelines were revised and
artesunate injection was recommended for severe malaria. So it is the
same with other ACTs, vaccines and some other medicines.
(Participant from MoHSW)
Promotion of medicines by the pharmaceutical
industry. Some informants accused medicine promotion for
influencing prescription practices. They were concerned that the
medicines recommended for addition in the STG were there
because of these types of influence. Two informants said:
The second and most important point is that selection was the direct
influence of medical representatives […]. They come here and talk to the
doctors and they give them some free samples, what they get in return we
do not know. With time doctors get used to these medicines and then they
force their inclusion in the hospital formularies and later into the STG/
NEML. (Participant from Hospital)
Lobbying by medical representatives is a problem. This hospital has a
policy that medical representatives should make presentations in the
meetings but sometimes they do not do that, they follow us into our
offices to convince us to prescribe their products. They give gifts and
some other things. Honestly, this is a common practice. (Participant
from Hospital)
To elaborate more on this practice, one informant said she used
her experience and sometimes gathered evidence from journals.
When she was asked to give the name of the journal, she said:
Oooh! my Goodness I cannot remember the journal, but I can link you
with those individuals at […] pharmaceutical companies and they can
give you that information. (Participant from Hospital)
In the informal interviews, drug representatives acknowledged
that they persuade healthcare workers to procure and prescribe
their products, and they do this by giving them free medicine
samples and gifts such as stationery, refrigerators and televisions.
The Approval of the STG/NEML
The National Medicines and Therapeutic Committee (NMTC)
is responsible for the approval of treatment guidelines and
formularies in Tanzania and the PSS acts as the secretariat for
this committee. The newly formed committee is multidisciplinary
and consists of 18 members (Figure 3), with the Chief Medical
Officer and the Assistant Director of PSS as the chairperson and
secretary, respectively.
Process. The updated draft of the STG/NEML was submit-
ted to the NMTC by the secretariat for approval in September
2012; about 130 new medicines were proposed to be added and
five to be deleted. This draft was submitted without a summary of
the changes and or the rationales behind them. Therefore the
approval process proceeded first with the explanations given by
the secretariat about the changes made in each chapter, followed
by brief discussions. An excerpt from one of the document reads:
The committee was taken through the reviewed STG and NEML,
chapter by chapter. In each chapter presentations, the major changes
which were made, in comparison to the STG/NEML edition of 2007,
were explained to the panel. The NMTC members discussed and made
recommendations.
Criteria used in the approval process and use of
evidence. There was no specific set of criteria used by the
NMTC to approve each of the proposed changes. However,
through document reviews, we found that the proposal to add
clindamycin injection for the management of malaria in pregnan-
cy was rejected because of safety and affordability concerns. The
committee also ordered the secretariat to shorten the NEML,
citing budget limitations as the only factor. This shows that to a
certain extent some criteria were considered but again were not
supported by evidence. One informant who participated in the
approval process said:
Is an evidence-based process used by the National Medicines and
Therapeutic Committee at the moment? I don’t think so. Is the
committee applying an evidence-based framework in decision-making
processes? I don’t think that’s what is being done at the moment.
(Participant from the MoHSW)
The fourth edition of the STG/NEML was released in July
2013, and contained nearly all the medicines that were initially
proposed for addition. In contrast to the previous editions, the new
STG/NEML contains, as appendices, application forms for
addition, deletion and change of dosage form, strength and
indication of the listed medicines. The guiding criteria include
efficacy, safety, cost-effectiveness, cost comparison and budgetary
impact. These criteria must be supported by relevant evidence,
such as the results of clinical trials conducted in Tanzania. An
excerpt from the application form reads:
Reasons why the proposed drug is preferred to drugs already in the
NEML (Please attach not more than five supporting pieces of evidence
with respect to efficacy, safety, cost, cost-effectiveness, others). State
briefly the results of clinical trials conducted in Tanzania […]. If no
official trials, state personal experience and/or submit documentary
proof.
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Discussion
The most important finding derived from this study is that
essential medicines in Tanzania were largely selected through an
experience-based process, in contrast to the evidence-based
approach that was recommended by the WHO Expert Committee
on Selection and Use of Essential Medicines in 2002 [13]. The use
of an evidence-based approach has been documented as difficult to
apply in developing countries [37], and this is consistent with our
findings. The WHO Expert Committee usually publishes evidence
supporting its decisions [38], hence decision-makers in developing
countries can gauge the applicability of such evidence in their own
context during medicine selection. We found that this opportunity
was very rarely utilised in the case of Tanzania.
The review involved experts who were selected mostly from
referral hospitals and the Ministry of Health and Social Welfare in
a process that can be described as implicit and not sufficiently
consultative. Participation by a wide array of stakeholders is
important to ensure that the needs existing across all levels of the
healthcare system are reflected in the STG/NEML. The
effectiveness of guidelines is often compromised by the develop-
ment process, and those guidelines that are imposed by higher
levels have a high probability of being under-utilised or even
rejected by healthcare workers [39].
We found that efficacy, safety, availability and affordability were
the most commonly cited criteria employed in medicine selection.
These criteria are to a large extent consistent with those
recommended by the WHO [7]. Medicines to manage diseases
such as malaria, HIV/AIDS, TB and leprosy, which are managed
under vertical programmes, were adopted from international
guidelines that usually employ the best available evidence. In
addition, medical sales representatives were also considered to be
influential in medicine selection as they are viewed as the main
source of drug information for prescribers. Experience from East
Africa shows that medicine promotion is widespread and poorly
regulated and several studies have reported concerns about the
influence of these sales representatives in medicine selection
[40,41,42,43].
The criterion of cost-effectiveness was not used despite being
one of the most important criteria employed by medicine
management committees in developed countries to inform
formulary decisions [45,46,47,48]. This finding is not surprising,
considering the limited role of pharmacoeconomics in developing
countries [49]. Several studies have cited the low availability of
pharmacoeconomic studies in Tanzania [33,42,50] as the main
barrier, but this study found that a lack of training could also be an
important limitation. Studies have shown that, without training,
decision-makers cannot understand, translate or apply economic
evidence even when it is made available to them [47,48].
Experience rather than scientific evidence played a major role
in the decision-making processes. In the few cases where scientific
evidence was claimed to have been used, there was neither a
systematic search nor an appraisal of the evidence and evidence
summaries were not generated to aid decision-making. Even for
criteria such as availability and affordability, which are relatively
easy to apply compared to efficacy and safety, evidence also
mainly came from experience and not official sources such as the
TFDA, Medical Stores Department or the International Drug
Price Indicator Guide. This could be explained by the inexperi-
ence of the experts involved in the review process in using an
evidence-based approach, the lack of guidelines on how to do the
review and time constraints. Commitment to the use of research
evidence and the availability of adequate infrastructures, tools and
expertise are essential to facilitate evidence-informed decision-
making [44].
Strengths and Limitations
This study employed a qualitative approach, which is suitable
for phenomena of which prior knowledge or understanding is
limited [51,52]. The method enabled participants to give detailed
accounts of what they did, observed and experienced during the
revision process, hence limiting the influence of any pre-conceived
ideas held by the investigators. However, in-depth interviews have
a tendency to introduce recall bias due to incorrect memorisation
or failure to remember important aspects of the phenomenon
under investigation [29], which was evident in our study. Recall
bias was minimised because the study was conducted while the
revision of the guidelines was still ongoing, albeit in the final stages.
The expertise of the principle investigator in essential medicine
and the functioning of the medicine selection committees in
Tanzania was instrumental in conducting this study. The potential
influence of his prior experience on the interpretation and
discussion of the findings was minimised through observing a
well-accepted protocol for qualitative studies, and by involving co-
authors in the analysis of the data, as well as in other phases of the
study.
The committees were faced with many challenges in performing
the reviews. Firstly, it appears that they were not given any
training or guidelines about how to update the STG/NEML;
secondly, the majority were performing a review for the first time;
Figure 3. Composition of the National Medicines and Therapeutic Committee. *Three representatives.
doi:10.1371/journal.pone.0084824.g003
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thirdly, they were not given sufficient time or other resources to
carry out the review and, lastly, even the organisers were
constrained by limited capacity and resources to carry out a
smooth review process. Therefore we believe that all those who
were involved performed the review of the STG/NEML to the
best of their ability. This paper has thus identified areas that can
be improved in future reviews.
Conclusions
Recent decisions about the selection of essential medicines in
Tanzania were made by committees of experts, who largely use
experience and discretionary judgement, leaving evidence with
only a limited role in decision-making processes. This practice
increases the risk of adopting ineffective and costly interventions
that may not be worth implementing. Because of this, the health
authorities in Tanzania should take the necessary measures to
ensure that limited health resources are allocated to proven
interventions with the greatest potential to reduce the burden of
disease and meet other public health goals. This can be achieved
through the systematic application of relevant evidence-based
criteria in priority-setting decisions between competing interven-
tions. There may be several reasons for the current limited use of
evidence in the decision-making process, but one hypothesis that
remains to be explored is whether training experts in evidence-
based decision-making would lead to a better and more explicit
use of evidence.
Acknowledgments
We thank Ana Lorena Ruano, the Priority-Setting Research Group at UIB
and the two reviewers for their constructive comments on early drafts of the
manuscript. We also thank our interviewees for consenting to participate in
the study.
Author Contributions
Analyzed the data: ATM EAK OFN BR. Wrote the paper: ATM EAK FN
OFN BR. Coded the data: ATM. Conceived and designed the study: ATM
EAK FN OFN BR. Collected the Data: ATM.
References
1. WHO (2004) Equitable access to essential medicines: a framework for collective
action. Geneva: World Health Organization.
2. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HGM, et al.
(2011) Differences in the availability of medicines for chronic and acute
conditions in the public and private sectors of developing countries. Bull World
Health Organ 89: 412–421.
3. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R (2009) Medicine prices,
availability, and affordability in 36 developing and middle-income countries: a
secondary analysis. Lancet 373: 240–249.
4. WHO (2011) The world medicine situation. Geneva, Switzerland: World Health
Organization.
5. United Nations (2008) The Millennium Development Goals Report (MDG Goal
8E). New York.
6. WHO (2008) The world health report 2008: primary health care now more than
ever. Geneva: World Health Organization.
7. WHO (2003) The selection and use of essential medicines. Technical Report
Series No 914: 15 Geneva: World Health Organization.
8. Holloway C, Green T, Carandang E, Hogerzeil H, Laing R, et al. (2003)
Managing the formulary process. In: Holloway C, editor. Drugs and
Therapeutic Committees: A Practical Guide. Geneva: World Health Organi-
zation.
9. Laing RO, Hogerzeil HV, Ross-Degnan D (2001) Ten recommendations to
improve use of medicines in developing countries. Health Policy Plan 16: 13–20.
10. Kafuko J, Bagenda D (1994) Impact of national standard treatment guidelines
on rational drug use in Uganda health facilities. Unicef: Kampala,Uganda.
11. Hogerzeil HV (2004) The concept of essential medicines: lessons for rich
countries. BMJ 329: 1169–1171.
12. Quick JD (2003) Essential medicines twenty-five years on: closing the access gap
Health Policy Plan 18: 1–3.
13. WHO (2002) Report of the WHO Expert Committee on the Selection and Use
of Essential Medicines Geneva: World Health Organization.
14. Laing R, Waning B, Gray A, Ford N, ‘t Hoen E (2003) 25 years of the WHO
essential medicines lists: progress and challenges. Lancet 361: 1723–1729.
15. Quick JD, Hogerzeil HV, Vela squez G, Rago L (2002) Twenty-five years of
essential medicines. Bull World Health Organ 80: 913–914.
16. WHO (1977) The selection of essential drugs: report of a WHO expert
committee. (Technical Report Series WHO no 615). World Health Organiza-
tion, Geneva.
17. WHO UNESCO (1978) Primary health care: Report of the International
Conference on Primary Health Care Geneva: World Health Organization.
18. Ministry of Health (1990) The National Health Policy. Dar es Salaam.
19. Ministry of Health (1991) Standard Treatment Guidelines and the National
Essential Drug List for Tanzania 1st ed. Dar es Salaam: The Government Press.
20. Ministry of Health and Social Welfare (2011) Tanzania Mainland National
Health Accounts 2009/10. Dar es Salaam.pp 20.
21. Department of Policy and Planning, Ministry of Health and Social Welfare
(2013) Health Sector Performance Profile Report 2011. Dar es Salaam. 55.
22. Department of Policy and Planning, Ministry of Health (2008) Annual Health
Statistical Abstract: Mainland Tanzania. Dar es Salaam.
23. Euro Health Group (2007) Drug Tracking Study Royal Danish Embassy, Dar es
Salaam-Tanzania.
24. National Bureau of Statistics (2013) 2012 Population Housing Census. Dar es
Salaam, United Republic of Tanzania.
25. National Bureau of Statistics, ICF Macro (2011) Tanzania Demographic and
Health Survey: 2010. Dar es Salaam, Tanzania.
26. NICE (2008) Guide to the methods of technology appraisal. London: National
Institute for Health and Clinical Excellence.
27. CADTH (2006) Guidelines for the economic evaluation of health technologies. :
Canadian Agency for Drugs and Technologies in Health: Ottawa, Canada.
28. WHO (2002) WHO Policy Perspective on Medicines: The Selection of Essential
Medicines. Geneva: World Health Organization.
29. Yin RK (2003) Case study research: Design and methods. Thousand Oaks, CA:
Sage.
30. Baxter P, Jack S (2008) Qualitative Case Study Methodology: Study Design and
Implementation for Novice Researchers. The Qualitative Report 13: 544–559.
31. Sandelowski M (2000) Focus on Research Methods Whatever Happened to
Qualitative Description? Res Nurs Health 23: 334–340.
32. Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting
qualitative research (COREC): a 32-item checklist for interviews and focus
groups. Int J Quality Car 19: 349–357.
33. Mori AT, Robberstad B (2012) Pharmacoeconomics and its implication on
priority-setting for essential medicines in Tanzania: a systematic review BMC
Med Inform Decis Mak 12: 110. doi:10.1186/1472-6947-12-110.
34. McLellan E, MacQueen KM, Niedig JL (2003) Beyond the qualitative interview:
Data preparation and transcription. Field Methods 15: 63–84.
35. Green J, Thorogood N (2009) Qualitative Methods for Health Research.
London: Sage Publications Ltd.
36. CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, et al. (2011)
The importance of early treatment with tranexamic acid in bleeding trauma
patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Lancet 377: 1096–1101.
37. Robertson J, Hill SR (2007) The Essential Medicines List for a Global Patient
Population. Clin Pharmacol Ther 82: 498–500.
38. WHO (2012) The Selection and Use of Essential Medicines: Report of the
WHO Expert Committee, 2011. Geneva: World Health Organization.
39. Orem JN, Wavamunno JB, Bakeera SK, Criel B (2011) Do guidelines influence
the implementation of health programs? – Uganda’s experience. Implement Sci
7: doi:10.1186/1748-5908-1187-1198.
40. Holly AN, Durrheim D, Rima S (2003) The process of changing national
malaria treatment policy: lessons from country-level studies. Health Policy Plan
19: 356–370.
41. Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, et al. (2007)
The challenges of changing national malaria drug policy to artemisinin-based
combinations in Kenya. Malar J 6: 72 doi:10.1186/1475-2875-6-72.
42. Mori AT, Kaale EA (2012) Priority setting for the implementation of
artemisinin-based combination therapy policy in Tanzania: Evaluation against
the accountability for reasonableness framework. Implement Sci 7: 18.
doi:10.1186/1748-5908-7-18.
43. Nanyunja M, Orem JN, Kato F, Kaggwa M, Katureebe C, et al. (2011) Malaria
Treatment Policy Change and Implementation: The Case of Uganda. Malar
Res Treat: doi:10.4061/2011/683167.
44. Ellen ME, Leon G, Bouchard G, Lavis JN, Ouimet M, et al. (2013) What
supports do health system organizations have in place to facilitate evidence-
informed decision-making? a qualitative study. Implement Sci 8: 84.
doi:10.1186/1748-5908-8-84.
45. Anell A (2004) Priority setting for pharmaceuticals; The use of health economic
evidence by reimbursement and clinical guidance committees. Eur J Health
Econ 5: 28–35.
Selection of Essential Medicines in Tanzania
PLOS ONE | www.plosone.org 9 January 2014 | Volume 9 | Issue 1 | e84824
46. Odedina F, Sullivan J, Nash R, Clemmons C (2002) Use of pharmacoeconomic
data in making hospital formulary decisions. Am J Health Syst Pharm 59: 1441–
1444.
47. Chen LC, Ashcroft DM, Elliott RA (2007) Do economic evaluations have a role
in decision-making in Medicine Management Committees? A qualitative study.
Pharm World Sci 29: 661e670.
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